Precision BioSciences Inc (DTIL)
10.57
-0.36
(-3.29%)
USD |
NASDAQ |
May 10, 16:00
10.57
0.00 (0.00%)
After-Hours: 19:12
Precision BioSciences SG&A Expense (Quarterly): 8.539M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 8.539M |
September 30, 2023 | 9.633M |
June 30, 2023 | 9.83M |
March 31, 2023 | 11.09M |
December 31, 2022 | 10.02M |
September 30, 2022 | 10.28M |
June 30, 2022 | 10.44M |
March 31, 2022 | 10.68M |
December 31, 2021 | 10.59M |
September 30, 2021 | 9.638M |
June 30, 2021 | 9.938M |
March 31, 2021 | 9.498M |
Date | Value |
---|---|
December 31, 2020 | 9.20M |
September 30, 2020 | 8.534M |
June 30, 2020 | 8.703M |
March 31, 2020 | 9.615M |
December 31, 2019 | 8.479M |
September 30, 2019 | 7.052M |
June 30, 2019 | 6.50M |
March 31, 2019 | 4.995M |
December 31, 2018 | 4.646M |
September 30, 2018 | 3.251M |
June 30, 2018 | 3.13M |
March 31, 2018 | 2.646M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
6.50M
Minimum
Jun 2019
11.09M
Maximum
Mar 2023
9.382M
Average
9.633M
Median
Sep 2023
SG&A Expense (Quarterly) Benchmarks
Altimmune Inc | 4.332M |
BioVie Inc | 2.254M |
Adial Pharmaceuticals Inc | 1.519M |
Gritstone Bio Inc | 7.916M |
Humacyte Inc | 6.002M |